EZH2 and diffuse large B-cell lymphoma: While EZH2 inhibitors are not as cytotoxic in DLBCL with increased EZH2 as they are in DLBCL with activating mutations in EZH2 (see Section 2.4), they still inhibit growth and may be effective in combination therapies (182).